Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276852 | 0.72 | L3MBTL1 (0.36) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL8718483 | 0.69 | L3MBTL1 (0.34) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL379577 | 0.67 | — | — | |
| SCHEMBL8721001 | 0.67 | L3MBTL1 (0.33) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL237154 | 0.67 | — | — | |
| SCHEMBL7533174 | 0.67 | TP53 (0.36) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL9231825 | 0.67 | L3MBTL1 (0.33) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL181792 | 0.67 | — | — | |
| SCHEMBL11731209 | 0.67 | FDPS (0.43) | L3MBTL1FDPSMMP1MMP2MMP3 | |
| SCHEMBL30602696 | 0.67 | L3MBTL1 (0.38) | L3MBTL1FDPSMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | FREY LISA F (US) | 2002-08-08 | — | — | US | claimed |
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | FREY LISA F (US) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | EDNRA, EDNRB, AGTR2 | L3MBTL1 4872/4885FDPS 1320/4885MMP1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.